
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/651591/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	4.5	11
2	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
3	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	10
4	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. Brain, Behavior, and Immunity, 2022, 99, 147-156.	4.1	2
5	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	2
6	Editorial: Women and the Pandemic. Archives of Women's Mental Health, 2022, 25, 255.	2.6	0
7	Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. Brain, Behavior, and Immunity, 2022, 103, 50-60.	4.1	4
8	Editorial: Sex and the Suffering Brain - A Call for Sex-Stratified Analyses in Psychiatric Research. Frontiers in Psychiatry, 2022, 13, 849009.	2.6	2
9	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biological Psychiatry, 2022, 92, 552-562.	1.3	15
10	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. Scientific Reports, 2022, 12, 6652.	3.3	2
11	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry, 2022, 79, 677.	11.0	6
12	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
13	Omegaâ€3 fatty acids and neurocognitive ability in young people at ultraâ€high risk for psychosis. Microbial Biotechnology, 2021, 15, 874-881.	1.7	10
14	Prediction of clinical outcomes beyond psychosis in the ultraâ€high risk for psychosis population. Microbial Biotechnology, 2021, 15, 642-651.	1.7	11
15	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
16	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
17	Effect of childhood physical abuse on social anxiety is mediated via reduced frontal lobe and amygdala-hippocampus complex volume in adult clinical high-risk subjects. Schizophrenia Research, 2021, 227, 101-109.	2.0	13
18	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021, 78, 195.	11.0	125

#	Article	IF	CITATIONS
19	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
20	Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. Journal of Psychiatric Research, 2021, 136, 428-434.	3.1	17
21	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. Translational Psychiatry, 2021, 11, 312.	4.8	7
22	Novel Gyrification Networks Reveal Links with Psychiatric Risk Factors in Early Illness. Cerebral Cortex, 2021, , .	2.9	2
23	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. ELife, 2021, 10, .	6.0	7
24	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. Schizophrenia Research, 2021, 236, 48-53.	2.0	6
25	The association between migrant status and transition in an ultra-high risk for psychosis population. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 943-952.	3.1	5
26	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
27	Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. Schizophrenia Bulletin, 2021, 47, 849-863.	4.3	13
28	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biological Psychiatry, 2020, 87, 243-252.	1.3	48
29	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. Psychological Medicine, 2020, 50, 2034-2045.	4.5	18
30	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. Schizophrenia Research, 2020, 226, 52-60.	2.0	8
31	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.	2.0	27
32	Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 539-548.	3.1	9
33	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.0	23
34	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. Schizophrenia Research, 2020, 216, 255-261.	2.0	8
35	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. Behaviour Research and Therapy, 2020, 124, 103527.	3.1	16
36	T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES. Schizophrenia Bulletin, 2020, 46, S238-S239.	4.3	0

#	Article	IF	CITATIONS
37	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2020, 46, S244-S245.	4.3	0
38	EEG Microstate Differences in Medicated vs. Medication-NaÃ ⁻ ve First-Episode Psychosis Patients. Frontiers in Psychiatry, 2020, 11, 600606.	2.6	15
39	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6
40	Editorial. Archives of Women's Mental Health, 2020, 23, 739-740.	2.6	0
41	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
42	EEG microstates as biomarker for psychosis in ultra-high-risk patients. Translational Psychiatry, 2020, 10, 300.	4.8	51
43	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. Schizophrenia Bulletin, 2020, 46, S104-S104.	4.3	0
44	Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?. Schizophrenia Research, 2020, 220, 275-277.	2.0	3
45	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2020, 218, 48-54.	2.0	8
46	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study. European Psychiatry, 2020, 63, e25.	0.2	14
47	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.3	14
48	Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders. Schizophrenia Research, 2020, 218, 267-275.	2.0	24
49	Menopause and Mental Health. Mental Health and Illness Worldwide, 2020, , 147-173.	0.1	5
50	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Frontiers in Psychiatry, 2020, 11, 552175.	2.6	5
51	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 853-858.	1.7	11
52	Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis. Microbial Biotechnology, 2019, 13, 969-976.	1.7	6
53	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World Journal of Biological Psychiatry, 2019, 20, 545-554.	2.6	37
54	Vulnerability and Protective Factors for Mental Health: A Rereading in Gender Perspective. , 2019, , 25-36.		1

#	Article	IF	CITATIONS
55	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. Schizophrenia Bulletin, 2019, 46, 252-260.	4.3	13
56	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. Frontiers in Psychiatry, 2019, 10, 393.	2.6	22
57	Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. European Psychiatry, 2019, 62, 30-37.	0.2	24
58	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.6	29
59	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. Scientific Reports, 2019, 9, 8516.	3.3	10
60	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
61	No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis. European Journal of Neuroscience, 2019, 50, 3060-3071.	2.6	3
62	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. Microbial Biotechnology, 2019, 13, 1283-1288.	1.7	5
63	Estrogens and SERMS as adjunctive treatments for schizophrenia. Frontiers in Neuroendocrinology, 2019, 53, 100743.	5.2	42
64	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0
65	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2019, 206, 67-74.	2.0	46
66	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	1.3	5
67	Bride price payment and women's autonomy: Findings from qualitative interviews from Nigeria. Women and Health, 2019, 59, 775-788.	1.0	6
68	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. World Journal of Biological Psychiatry, 2019, 20, 17-50.	2.6	31
69	Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. Schizophrenia Research, 2019, 210, 39-47.	2.0	67
70	Individualized prediction of psychosis in subjects with an at-risk mental state. Schizophrenia Research, 2019, 214, 18-23.	2.0	25
71	Gender differences in first selfâ€perceived signs and symptoms in patients with an atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 582-588.	1.7	22
72	Menopause and Mental Health. Mental Health and Illness Worldwide, 2019, , 1-27.	0.1	0

#	Article	IF	CITATIONS
73	Disorganized Gyrification Network Properties During the Transition to Psychosis. JAMA Psychiatry, 2018, 75, 613.	11.0	56
74	Sexually dimorphic subcortical brain volumes in emerging psychosis. Schizophrenia Research, 2018, 199, 257-265.	2.0	12
75	Clinical trajectories in the ultra-high risk for psychosis population. Schizophrenia Research, 2018, 197, 550-556.	2.0	54
76	The Frankfurt Complaint Questionnaire for selfâ€assessment of basic symptoms in the early detection of psychosis—Factor structure, reliability, and predictive validity. International Journal of Methods in Psychiatric Research, 2018, 27, e1600.	2.1	7
77	Letter from the Editor-in-Chief. Archives of Women's Mental Health, 2018, 21, 125-126.	2.6	0
78	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?. European Psychiatry, 2018, 52, 38-44.	0.2	9
79	Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. Microbial Biotechnology, 2018, 12, 66-73.	1.7	19
80	Outcome of individuals "not at risk of psychosis―and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP). Microbial Biotechnology, 2018, 12, 907-914.	1.7	3
81	Abnormal brain connectivity during error-monitoring in the psychosis high-risk state. Schizophrenia Research, 2018, 193, 261-262.	2.0	1
82	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. Schizophrenia Bulletin, 2018, 44, S132-S133.	4.3	5
83	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. Schizophrenia Bulletin, 2018, 44, S116-S116.	4.3	2
84	T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY. Schizophrenia Bulletin, 2018, 44, S199-S199.	4.3	0
85	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. Schizophrenia Bulletin, 2018, 44, S228-S228.	4.3	1
86	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. Schizophrenia Bulletin, 2018, 44, S378-S379.	4.3	1
87	Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis. Scientific Reports, 2018, 8, 16516.	3.3	1
88	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	11.0	251
89	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. Psychology Research and Behavior Management, 2018, Volume 11, 157-168.	2.8	8
90	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2018, 44, S99-S99.	4.3	1

#	Article	IF	CITATIONS
91	Sex and gender differences in schizophrenic psychoses—a critical review. Archives of Women's Mental Health, 2018, 21, 627-648.	2.6	140
92	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	627
93	The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. Psychiatry Research, 2018, 268, 21-27.	3.3	21
94	NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course. NPJ Schizophrenia, 2018, 4, 11.	3.6	41
95	Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume. Cellular Physiology and Biochemistry, 2018, 48, 1201-1214.	1.6	10
96	Dynamic prediction of transition to psychosis using joint modelling. Schizophrenia Research, 2018, 202, 333-340.	2.0	18
97	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. PLoS ONE, 2018, 13, e0196936.	2.5	3
98	Patient-Identified Priorities Leading to Attempted Suicide. Crisis, 2018, 39, 37-46.	1.2	5
99	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw110.	4.3	38
100	NEURAPROâ€E study protocol: a multicentre randomized controlled trial of omegaâ€3 fatty acids and cognitiveâ€behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Microbial Biotechnology, 2017, 11, 418-428.	1.7	55
101	Correlations between selfâ€rating and observerâ€rating of psychopathology in atâ€risk mental state and firstâ€episode psychosis patients: influence of disease stage and gender. Microbial Biotechnology, 2017, 11, 461-470.	1.7	11
102	Longitudinal determinants of client treatment satisfaction in an intensive firstâ€episode psychosis treatment programme. Microbial Biotechnology, 2017, 11, 354-362.	1.7	7
103	Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychological Medicine, 2017, 47, 1163-1178.	4.5	75
104	Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophrenia Research, 2017, 189, 111-116.	2.0	35
105	Sex and gender differences in mental disorders. Lancet Psychiatry,the, 2017, 4, 8-9.	7.4	334
106	Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.	11.0	216
107	Autonomy and Reproductive Rights of Married Ikwerre Women in Rivers State, Nigeria. Journal of Bioethical Inquiry, 2017, 14, 205-215.	1.5	4
108	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state. Biological Psychology, 2017, 126, 12-18.	2.2	1

#	Article	IF	CITATIONS
109	Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry,the, 2017, 4, 63-72.	7.4	104
110	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. Psychotherapy and Psychosomatics, 2017, 86, 292-299.	8.8	20
111	Estradiol Production Suppressed by Prolactin in at-risk Mental State and First Episode Psychosis Female Patients? Preliminary Results. European Psychiatry, 2017, 41, S267-S267.	0.2	1
112	The Current European Status. European Psychiatry, 2017, 41, S27-S27.	0.2	0
113	Long-term rates of remission and late psychotic transition of individuals at risk for psychosis. European Psychiatry, 2017, 41, S186-S186.	0.2	2
114	Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis. European Psychiatry, 2017, 41, S198-S198.	0.2	2
115	The Relationship Between Negative Symptoms and Cognitive Functioning in Patients with an at Risk Mental State for Psychosis. European Psychiatry, 2017, 41, S270-S271.	0.2	0
116	Stigma in early detection of psychosis: Subjective experiences of those concerned. European Psychiatry, 2017, 41, S387-S387.	0.2	0
117	Letter from the Editor-in-Chief. Archives of Women's Mental Health, 2017, 20, 241-241.	2.6	0
118	Verbal Learning and Memory in At-risk Mental State and First Episode Psychosis Patients and Their Correlates to Brain Structural Alterations. European Psychiatry, 2017, 41, S103-S103.	0.2	0
119	Duration of untreated psychosis/illness and brain volume changes in early psychosis. Psychiatry Research, 2017, 255, 332-337.	3.3	25
120	Prediction of conversion to psychosis in individuals with an at-risk mental state. Current Opinion in Psychiatry, 2017, 30, 209-219.	6.3	49
121	Working Together for Early Detection of Psychosis. European Psychiatry, 2017, 41, S6-S6.	0.2	0
122	Age-related brain structural alterations as an intermediate phenotype of psychosis. Journal of Psychiatry and Neuroscience, 2017, 42, 307-319.	2.4	32
123	Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences. Frontiers in Psychiatry, 2017, 8, 115.	2.6	22
124	Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. Frontiers in Psychiatry, 2017, 8, 206.	2.6	6
125	Education and Reproductive Autonomy: The Case of Married Nigerian Women. Narrative Inquiry in Bioethics, 2017, 7, 231-244.	0.1	8
126	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. Lecture Notes in Computer Science, 2017, 10541, 371-378.	1.3	4

#	Article	IF	CITATIONS
127	Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms. Frontiers in Psychiatry, 2016, 7, 189.	2.6	14
128	Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. NPJ Schizophrenia, 2016, 2, 16033.	3.6	42
129	The role of vulnerability factors in individuals with an at-risk mental state of psychosis. Neuropsychiatrie, 2016, 30, 18-26.	2.5	4
130	Early psychosis in young women. European Psychiatry, 2016, 33, S7-S7.	0.2	0
131	Sex and gender differences in schizophrenic psychoses. European Psychiatry, 2016, 33, S46-S46.	0.2	5
132	Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms. Schizophrenia Research, 2016, 175, 20-26.	2.0	15
133	High time for a paradigm shift in psychiatry. World Psychiatry, 2016, 15, 131-133.	10.4	6
134	Does menopausal transition really influence mental health? Findings from the prospective longâ€ŧerm <scp>Z</scp> urich study. World Psychiatry, 2016, 15, 146-154.	10.4	32
135	Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis. Translational Psychiatry, 2016, 6, e868-e868.	4.8	36
136	Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders. Neuropsychiatrie, 2016, 30, 191-197.	2.5	2
137	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin, 2016, 42, 732-743.	4.3	183
138	Neurocognition and Motor Functioning in the Prediction of Psychosis. Key Issues in Mental Health, 2016, , 116-132.	0.6	11
139	Early Detection and Intervention in Psychosis. Key Issues in Mental Health, 2016, , 179-189.	0.6	4
140	Neural oscillations in antipsychotic-naÃ ⁻ ve patients with a first psychotic episode. World Journal of Biological Psychiatry, 2016, 17, 296-307.	2.6	12
141	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. JAMA Psychiatry, 2016, 73, 113.	11.0	354
142	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naÃ ⁻ ve at-risk patients. World Journal of Biological Psychiatry, 2016, 17, 285-295.	2.6	43
143	Psychotropic Drugs and the Perinatal Period. , 2016, , 79-92.		2

144 Weibliche Rollen und psychische Gesundheit. , 2016, , 19-34.

#	Article	IF	CITATIONS
145	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. Journal of Psychiatry and Neuroscience, 2016, 41, 367-376.	2.4	36
146	Appropriateness of Care and Joint Decision-Making Strategies. , 2016, , 207-209.		0
147	At risk or not at risk? A metaâ€analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	10.4	209
148	Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology. NeuroSignals, 2015, 23, 71-83.	0.9	26
149	Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing. Neurolmage: Clinical, 2015, 9, 555-563.	2.7	21
150	Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment. Human Brain Mapping, 2015, 36, 5287-5300.	3.6	22
151	EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 2015, 30, 388-404.	0.2	390
152	Sex Differences in Cognitive Functioning in At-Risk Mental State for Psychosis, First Episode Psychosis and Healthy Control Subjects. European Psychiatry, 2015, 30, 242-250.	0.2	43
153	Orbitofrontal response to drug-related stimuli after heroin administration. Addiction Biology, 2015, 20, 570-579.	2.6	32
154	Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity. Brain, 2015, 138, 217-228.	7.6	22
155	Modulation of motivational salience processing during the early stages of psychosis. Schizophrenia Research, 2015, 166, 17-23.	2.0	44
156	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain, 2015, 138, 2059-2073.	7.6	132
157	Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. CNS Spectrums, 2015, 20, 122-129.	1.2	10
158	EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 2015, 30, 405-416.	0.2	318
159	Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution. Translational Psychiatry, 2015, 5, e533-e533.	4.8	41
160	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. NeuroImage: Clinical, 2015, 8, 230-237.	2.7	13
161	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. Schizophrenia Bulletin, 2015, 41, 919-929.	4.3	60
162	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. Schizophrenia Bulletin, 2015, 41, 471-482.	4.3	136

#	Article	IF	CITATIONS
163	Perinatal mental health service provision in Switzerland and in the UK. Swiss Medical Weekly, 2015, 145, w14011.	1.6	6
164	Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments. Swiss Medical Weekly, 2015, 145, w14099.	1.6	4
165	Altered prefrontal connectivity after acute heroin administration during cognitive control. International Journal of Neuropsychopharmacology, 2014, 17, 1375-1385.	2.1	16
166	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
167	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. Journal of Psychiatry and Neuroscience, 2014, 39, 239-248.	2.4	39
168	Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. Psychological Medicine, 2014, 44, 489-498.	4.5	43
169	THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?. Schizophrenia Research, 2014, 153, S23-S24.	2.0	0
170	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophrenia Bulletin, 2014, 40, 1140-1153.	4.3	369
171	Evidence for an agitated–aggressive syndrome predating the onset of psychosis. Schizophrenia Research, 2014, 157, 26-32.	2.0	20
172	Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses. Biological Psychiatry, 2014, 76, 289-296.	1.3	112
173	Gender differences in the psychopathology of emerging psychosis. Israel Journal of Psychiatry, 2014, 51, 85-92.	0.2	4
174	Gender and psychiatry. Israel Journal of Psychiatry, 2014, 51, 82-4.	0.2	0
175	Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology, 2013, 230, 299-308.	3.1	22
176	Help-seeking and pathways to care in the early stages of psychosis. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1033-1043.	3.1	59
177	Acute effects of heroin on emotions in heroinâ€dependent patients. American Journal on Addictions, 2013, 22, 598-604.	1.4	36
178	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Research, 2013, 209, 266-272.	3.3	114
179	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Research - Neuroimaging, 2013, 214, 102-108.	1.8	28
180	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology, 2013, 23, 196-204.	0.7	137

#	Article	IF	CITATIONS
181	Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?. Psychiatry Research, 2013, 210, 427-431.	3.3	17
182	2710 – Gender differences in the psychopathology of emerging psychosis. European Psychiatry, 2013, 28, 1.	0.2	1
183	S.10.03 Hyperprolactinemia in drug-naÃ ⁻ ve first-episode patients: data from EUFEST. European Neuropsychopharmacology, 2013, 23, S126.	0.7	0
184	The attenuated psychosis syndrome in DSM-5. Schizophrenia Research, 2013, 151, 295.	2.0	5
185	Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research, 2013, 147, 132-139.	2.0	48
186	P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin. European Neuropsychopharmacology, 2013, 23, S573-S574.	0.7	0
187	P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis. European Neuropsychopharmacology, 2013, 23, S277-S278.	0.7	0
188	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.0	1,222
189	Duration of untreated psychosis and cognitive functioning. Schizophrenia Research, 2013, 145, 43-49.	2.0	31
190	Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological Medicine, 2013, 43, 2571-2582.	4.5	85
191	Can cognitive deficits facilitate differential diagnosis between atâ€risk mental state for psychosis and depressive disorders?. Microbial Biotechnology, 2013, 7, 381-390.	1.7	16
192	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. International Journal of Neuropsychopharmacology, 2013, 16, 987-995.	2.1	69
193	Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study. Frontiers in Psychiatry, 2013, 4, 135.	2.6	27
194	Brain Connectivity Abnormalities Predating the Onset of Psychosis. JAMA Psychiatry, 2013, 70, 903.	11.0	94
195	Group Treatment for Depression in Mothers of Young Children Compared to Standard Individual Therapy. Psychopathology, 2013, 46, 94-101.	1.5	9
196	Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition. Schizophrenia Bulletin, 2013, 39, 1105-1114.	4.3	64
197	Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response. Journal of Clinical Psychopharmacology, 2013, 33, 193-198.	1.4	35
198	Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control. Neuropsychopharmacology, 2013, 38, 2231-2239.	5.4	50

#	Article	IF	CITATIONS
199	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology, 2013, 33, 258-261.	1.4	14
200	Violence against Women and Mental Health. Key Issues in Mental Health, 2013, , 167-174.	0.6	10
201	Do Subjects at Clinical High Risk for Psychosis Differ from those with a Genetic High Risk? - A Systematic Review of Structural and Functional Brain Abnormalities. Current Medicinal Chemistry, 2013, 20, 467-481.	2.4	55
202	Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study. PLoS ONE, 2013, 8, e71461.	2.5	27
203	Suicide attempts in the county of Basel: results from the WHO/EURO Multicentre Study on Suicidal Behaviour. Swiss Medical Weekly, 2013, 143, w13759.	1.6	19
204	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. Schizophrenia Bulletin, 2012, 38, 1234-1246.	4.3	139
205	Attempted Suicide in Immigrants from Turkey: A Comparison with Swiss Suicide Attempters. Psychopathology, 2012, 45, 366-373.	1.5	22
206	The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence. European Addiction Research, 2012, 18, 116-123.	2.4	17
207	Insular volume abnormalities associated with different transition probabilities to psychosis. Psychological Medicine, 2012, 42, 1613-1625.	4.5	50
208	Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies. Current Pharmaceutical Design, 2012, 18, 5070-5080.	1.9	53
209	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. Current Pharmaceutical Design, 2012, 18, 416-421.	1.9	12
210	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychological Medicine, 2012, 42, 1461-1473.	4.5	26
211	Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study. Schizophrenia Research, 2012, 142, 217-222.	2.0	52
212	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.3	85
213	Poster #52 DURATION OF UNTREATED ILLNESS/PSYCHOSIS AND COGNITIVE FUNCTIONING. Schizophrenia Research, 2012, 136, S110.	2.0	0
214	Poster #56 INSULAR VOLUME ABNORMALITIES ASSOCIATED WITH DIFFERENT TRANSITION PROBABILITIES TO PSYCHOSIS – A VOXEL-BASED MORPHOMETRY STUDY. Schizophrenia Research, 2012, 136, S111.	2.0	0
215	Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS. Schizophrenia Research, 2012, 136, S300.	2.0	1
216	Different duration of atâ€risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. Human Brain Mapping, 2012, 33, 2281-2294.	3.6	63

#	Article	IF	CITATIONS
217	First selfâ€perceived signs and symptoms in emerging psychosis compared with depression. Microbial Biotechnology, 2012, 6, 455-459.	1.7	3
218	Cingulate Volume Abnormalities in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 495-504.	1.9	21
219	Cost of attempted suicide: a retrospective study of extent and associated factors. Swiss Medical Weekly, 2012, 142, w13648.	1.6	29
220	Pituitary volume increase during emerging psychosis. Schizophrenia Research, 2011, 125, 41-48.	2.0	57
221	Sexual Dysfunction in First-Episode Schizophrenia Patients. Journal of Clinical Psychopharmacology, 2011, 31, 274-280.	1.4	99
222	Neuroanatomical Abnormalities That Predate the Onset of Psychosis. Archives of General Psychiatry, 2011, 68, 489.	12.3	227
223	A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression. Journal of Clinical Psychiatry, 2011, 72, 986-993.	2.2	195
224	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. Journal of Psychiatric Research, 2010, 44, 447-453.	3.1	82
225	Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2010, 34, 1207-1222.	6.1	287
226	QEEG SPECTRAL POWER AND NEGATIVE SYMPTOMS IN THE DETECTION OF BEGINNING PSYCHOSIS. Schizophrenia Research, 2010, 117, 482-483.	2.0	0
227	The Self-screen-Prodrome as a short screening tool for pre-psychotic states. Schizophrenia Research, 2010, 123, 217-224.	2.0	30
228	EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophrenia Research, 2010, 123, 208-216.	2.0	42
229	Neural effects of heroin — Relation to anxiety stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 816-817.	4.8	2
230	Hyperprolactinaemia in early psychosis—not only due to antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1342-1344.	4.8	72
231	P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis. European Neuropsychopharmacology, 2010, 20, S78.	0.7	0
232	Prospects for the classification of mental disorders in women. European Psychiatry, 2010, 25, 189-196.	0.2	53
233	Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. Current Topics in Behavioral Neurosciences, 2010, 8, 155-171.	1.7	63
234	Domestic violence against women: Definitions, epidemiology, risk factors and consequences. Swiss Medical Weekly, 2010, 140, w13099.	1.6	67

#	Article	IF	CITATIONS
235	Title is missing!. Therapeutische Umschau Revue Therapeutique, 2010, 067, 0547-0547.	0.1	0
236	Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?. Journal of Psychiatry and Neuroscience, 2010, 35, 214-5; author reply 215.	2.4	2
237	Prediction of Caseness for Mental Pathology in Swiss Conscripts: The Self-Screen Prodrome. Military Medicine, 2009, 174, 1270-1275.	0.8	10
238	The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?. Psychological Medicine, 2009, 39, 1781-1782.	4.5	15
239	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). American Journal of Psychiatry, 2009, 166, 675-682.	7.2	284
240	Can Cortical Thickness Asymmetry Analysis Contribute to Detection of At-Risk Mental State and First-Episode Psychosis?: A Pilot Study. Radiology, 2009, 250, 212-221.	7.3	64
241	EEG: a helpful tool in the prediction of psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 257-262.	3.2	26
242	Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up. Biological Psychiatry, 2009, 66, 1023-1030.	1.3	244
243	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. Schizophrenia Research, 2009, 113, 109-110.	2.0	14
244	Negative symptoms in neuroleptic-naÃ ⁻ ve patients with first-episode psychosis correlate with QEEG parameters. Schizophrenia Research, 2009, 115, 231-236.	2.0	22
245	The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review. Current Pharmaceutical Design, 2009, 15, 2535-2549.	1.9	191
246	Intervention in Individuals at Ultra-High Risk for Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1206-1212.	2.2	258
247	Insular pathology in the at-risk mental state. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 254-255.	3.2	4
248	Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research, 2008, 106, 108-114.	2.0	210
249	STRATEGIES FOR IMPROVING THE PREDICTION OF PSYCHOSIS. Schizophrenia Research, 2008, 102, 155.	2.0	1
250	Anterior cingulate pathology in the prodromal stage of schizophrenia. NeuroImage, 2008, 39, 553-554.	4.2	34
251	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, The, 2008, 371, 1085-1097.	13.7	964
252	Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis. Australian and New Zealand Journal of Psychiatry, 2007, 41, 554-554.	2.3	2

#	Article	IF	CITATIONS
253	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology, 2007, 10, S1-207.	2.1	55
254	Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. British Journal of Psychiatry, 2007, 191, s69-s75.	2.8	128
255	Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis. European Psychiatry, 2007, 22, 264-264.	0.2	8
256	Indication and impact of mentoring models. European Psychiatry, 2007, 22, S24.	0.2	0
257	Psychotic experiences in the general population: A twenty-year prospective community study. Schizophrenia Research, 2007, 92, 1-14.	2.0	265
258	Neuropsychological deficits in individuals with an at risk mental state for psychosis — Working memory as a potential trait marker. Schizophrenia Research, 2007, 97, 14-24.	2.0	88
259	Regional Gray Matter Volume Abnormalities in the At Risk Mental State. Biological Psychiatry, 2007, 61, 1148-1156.	1.3	295
260	The Basel earlyâ€detectionâ€ofâ€psychosis (FEPSY)â€study – design and preliminary results. Acta Psychiatrica Scandinavica, 2007, 115, 114-125.	4.5	187
261	The forthcoming role of treatment with oestrogens in mental health. Swiss Medical Weekly, 2007, 137, 565-72.	1.6	28
262	Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. International Journal of Psychiatry in Clinical Practice, 2006, 10, 174-181.	2.4	5
263	Early detection and treatment of schizophrenia: how early?. Acta Psychiatrica Scandinavica, 2006, 113, 73-80.	4.5	73
264	Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 201-206.	3.2	46
265	Radiological findings in individuals at high risk of psychosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 229-233.	1.9	47
266	Oestrogen-A Protective Factor in Schizophrenia?. Current Psychiatry Reviews, 2006, 2, 339-352.	0.9	9
267	Group Psychotherapy for Depression in Early Stages of Motherhood. , 2005, 173, 167-181.		Ο
268	Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology, 2005, 15, 399-409.	0.7	516
269	Estrogens and Schizophrenia. , 2005, , 31-52.		21
270	The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research, 2005, 78, 147-156.	2.0	89

#	Article	IF	CITATIONS
271	Cannabis and risk of psychosis. Swiss Medical Weekly, 2004, 134, 659-63.	1.6	8
272	Postpartum depression: do we still need this diagnostic term?. Acta Psychiatrica Scandinavica, 2003, 108, 51-56.	4.5	64
273	Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY). Acta Psychiatrica Scandinavica, 2003, 108, 152-155.	4.5	54
274	Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain. Gynecological Endocrinology, 2003, 17, 363-378.	1.7	0
275	Oestrogens and schizophrenia. Current Opinion in Psychiatry, 2003, 16, 187-192.	6.3	26
276	Late-Onset Schizophrenia Versus Paranoid Psychoses. American Journal of Geriatric Psychiatry, 2003, 11, 595-604.	1.2	5
277	Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?. American Journal of Geriatric Psychiatry, 2003, 11, 595-604.	1.2	15
278	Östrogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und GynÄ k ologie. Geburtshilfe Und Frauenheilkunde, 2002, 62, 429-435.	1.8	2
279	Oestrogen effects in schizophrenia and their potential therapeutic implications - Review. Archives of Women's Mental Health, 2002, 5, 111-118.	2.6	57
280	Oestrogens and schizophrenia - Introduction. Archives of Women's Mental Health, 2002, 5, 91-92.	2.6	16
281	Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatrica Scandinavica, 2000, 102, 58-62.	4.5	175
282	Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia. , 1999, , 249-258.		0
283	The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 189-202.	3.2	53
284	Gonadal function and its influence on psychopathology. Archives of Women's Mental Health, 1998, 1, 15-26.	2.6	30
285	The ABC schizophrenia study: a preliminary overview of the results. Social Psychiatry and Psychiatric Epidemiology, 1998, 33, 380-386.	3.1	196
286	Causes and Consequences of the Gender Difference in Age at Onset of Schizophrenia. Schizophrenia Bulletin, 1998, 24, 99-113.	4.3	289
287	Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. Psychological Medicine, 1998, 28, 351-365.	4.5	144
288	What do we really know about late-onset schizophrenia?. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 195-208.	3.2	59

#	Article	IF	CITATIONS
289	Changing patterns of mental health care in Germany. International Journal of Law and Psychiatry, 1996, 19, 391-411.	0.9	8
290	Case management for schizophrenic patients at risk for rehospitalization: A case control study. European Archives of Psychiatry and Clinical Neuroscience, 1995, 246, 29-36.	3.2	29
291	Symptom Assessment in Casenotes and the Clinical Diagnosis of Schizophrenia. Psychopathology, 1995, 28, 131-139.	1.5	7
292	Late-onset Schizophrenia and Late Paraphrenia. Schizophrenia Bulletin, 1995, 21, 345-354.	4.3	27
293	The Epidemiology of Early Schizophrenia. British Journal of Psychiatry, 1994, 164, 29-38.	2.8	178
294	Can Estradiol Modulate Schizophrenic Symptomatology?. Schizophrenia Bulletin, 1994, 20, 203-214.	4.3	263
295	Further evidence for a specific role of estradiol in schizophrenia?. Biological Psychiatry, 1994, 36, 492-494.	1.3	97
296	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry, 1994, 36, 137-139.	1.3	96
297	Higher morbidity risk for schizophrenia in males: Fact or fiction?. Comprehensive Psychiatry, 1994, 35, 39-49.	3.1	19
298	Organic factors and the clinical features of late paranoid psychosis: a comparison with Alzheimer's disease and normal ageing. Acta Psychiatrica Scandinavica, 1994, 89, 335-340.	4.5	21
299	Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany. Psychiatric Services, 1994, 45, 818-822.	2.0	9
300	Validation of Danish case register diagnosis for schizophrenia. Acta Psychiatrica Scandinavica, 1994, 90, 196-203.	4.5	87
301	Schizophrenia and oestrogens — is there an association?. European Archives of Psychiatry and Clinical Neuroscience, 1993, 242, 323-328.	3.2	143
302	The Influence of Age and Sex on the Onset and Early Course of Schizophrenia. British Journal of Psychiatry, 1993, 162, 80-86.	2.8	594
303	Compulsory admission of psychiatric patients – an international comparison. Acta Psychiatrica Scandinavica, 1993, 87, 231-236.	4.5	126
304	Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychological Medicine, 1993, 23, 925-940.	4.5	249
305	Does case management reduce the rehospitalization rate?. Acta Psychiatrica Scandinavica, 1992, 86, 445-449.	4.5	78
306	IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research, 1992, 6, 209-223,	2.0	521

#	Article	IF	CITATIONS
307	Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophrenia Research, 1992, 6, 114-115.	2.0	20
308	First onset and early symptomatology of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 109-118.	3.2	180
309	ls age of onset in schizophrenia influenced by marital status?. Social Psychiatry and Psychiatric Epidemiology, 1992, 27, 122-128.	3.1	39
310	Factors influencing compulsory admission of psychiatric patients. Psychological Medicine, 1991, 21, 197-208.	4.5	88
311	Community care in child psychiatry. Social Psychiatry and Psychiatric Epidemiology, 1991, 26, 28-33.	3.1	13
312	Schizophrenia — a disease of young single males?. European Archives of Psychiatry and Neurological Sciences, 1989, 239, 210-212.	0.9	31
313	How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychological Medicine, 1989, 19, 903-918.	4.5	226
314	Central Institute of Mental Health, Mannheim, West Germany. Psychological Medicine, 1985, 15, 417-431.	4.5	3
315	Early Detection of Psychosis - Helpful or Stigmatizing Experience for Those Concerned?. Key Issues in Mental Health, 0, , 69-82.	0.6	0
316	Increased Symptom Consolidation Preceding Transition to Psychosis: A Phenomenological Network Study. SSRN Electronic Journal, 0, , .	0.4	1
317	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youth at Ultra-High Risk for Psychosis. SSRN Electronic Journal, 0, , .	0.4	0
318	Professional Conduct and Handling Misconduct in Psychotherapy: Ethical Practice between Boundaries, Relationships, and Reality. , 0, , 1001-1018.		0
319	The relationship between grey matter volume and clinical and functional outcomes in people at clinical high risk for psychosis. Schizophrenia Bulletin Open, 0, , .	1.7	0